State of Peptide Therapy Access 2026
The first national report on peptide therapy clinic distribution across the United States — built from a verified directory of 388 providers in all 50 states (plus DC and Puerto Rico) and 272 cities.
Published 2026-04-21 · PeptideProbe Editorial Team · CC BY 4.0
Five Key Findings
Insurance coverage is effectively absent — only 4% of clinics accept it
Despite widespread commercial insurance coverage for FDA-approved peptides like semaglutide, just 16 of 388 peptide therapy clinics in our directory accept any form of insurance. This makes peptide therapy an overwhelmingly cash-pay specialty and drives the practical economics of access — especially for research peptides like BPC-157, which are never covered.
BPC-157 is the most-offered peptide nationally, ahead of all GLP-1s
305 of 388 clinics (79%) offer BPC-157 — more than semaglutide, tirzepatide, or any hormone-optimization peptide. This reflects the cash-pay economics of the specialty: clinics lead with the peptides that produce visible results (recovery, gut healing) rather than the ones insurance will eventually reimburse.
West Coast telehealth adoption is 2.7× the Mountain/Southwest rate
Telehealth access varies enormously by region. West Coast clinics offer telehealth at 46%, versus just 17% in the Mountain/Southwest region. The Southeast and Midwest sit between the two at 25–27%. This regional split means "peptide therapy telehealth" is not a uniform national market — it's a West Coast and select-state phenomenon that the rest of the country is still catching up to.
246 clinics offer at least one GLP-1 — the fastest-growing category
246 of 388 clinics (63%) offer at least one GLP-1 (semaglutide, tirzepatide, or AOD-9604). The GLP-1 category has the widest price range in the dataset ($150–$900/month), reflecting both the gap between compounded and brand options and the coming expansion to retatrutide and orforglipron.
California alone has 39 providers — 10% of the national total
Peptide clinic density is heavily concentrated. The top 5 states (California, Texas, Florida, Arizona, Illinois) host 121 of 388 providers (31% of the market). For patients in lower-density states, telehealth is often the only practical access channel — which amplifies the regional telehealth disparity described in Finding 3.
Top 10 States by Provider Count
| State | Providers | Telehealth % | Insurance % | Free consult % |
|---|---|---|---|---|
| CA | 39 | 41% | 3% | 33% |
| TX | 31 | 23% | 6% | 26% |
| FL | 20 | 35% | 5% | 30% |
| AZ | 17 | 18% | 0% | 12% |
| IL | 14 | 43% | 0% | 0% |
| GA | 12 | 25% | 0% | 0% |
| NJ | 12 | 25% | 0% | 8% |
| MN | 11 | 27% | 0% | 18% |
| NC | 10 | 10% | 10% | 0% |
| MO | 10 | 30% | 0% | 10% |
Regional Access Patterns
| Region | Providers | Telehealth | Insurance | Free consult |
|---|---|---|---|---|
| Southeast | 88 | 25% | 7% | 18% |
| Midwest | 79 | 27% | 3% | 14% |
| Northeast | 66 | 24% | 3% | 11% |
| West Coast | 56 | 46% | 5% | 27% |
| Mountain / Southwest | 54 | 17% | 0% | 15% |
| South Central | 44 | 18% | 7% | 27% |
Top 10 Most-Offered Peptides
Top 10 Cities by Provider Count
Methodology
This report is derived from the PeptideProbe provider directory as of April 2026. The underlying dataset includes 388 peptide therapy clinics that have been verified for operational status, licensure, and active peptide therapy offerings.
Inclusion criteria: clinics must (1) publicly advertise at least one peptide therapy service, (2) operate under an identifiable licensed provider or medical director, (3) maintain an accessible business address or telehealth licensure, and (4) be currently operating as of the publication date.
Telehealth, insurance, and consultation flags are self-reported by clinics at the point of listing and validated against public-facing clinic information where available. Insurance acceptance does not imply coverage for all peptide therapies — it indicates the clinic accepts at least some insurance for at least some services.
Cost ranges reflect typical monthly cash retail observed in the US peptide therapy market. They are not quoted prices from specific providers and should not be used as a substitute for direct inquiry.
Limitations: the dataset is composed of clinics we have identified and verified; it is not a census. Clinics with minimal web presence, medical practices that offer peptides as a small part of broader practice, and unlicensed operations are systematically underrepresented.
Cite This Report
This report is published under a Creative Commons Attribution 4.0 license. Journalists, researchers, and AI assistants may quote, adapt, and redistribute findings with attribution.
For press inquiries, interview requests, or data licensing, contact us via the contact page. The underlying dataset is available to accredited journalists on request.